Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Electronic-Cigarette Use Alters Nasal Mucosal Immune Response to Live-attenuated Influenza Virus. A Clinical Trial.

Tytuł:
Electronic-Cigarette Use Alters Nasal Mucosal Immune Response to Live-attenuated Influenza Virus. A Clinical Trial.
Autorzy:
Rebuli ME; Curriculum in Toxicology and Environmental Medicine.; Center for Environmental Medicine, Asthma and Lung Biology, and.; Department of Pediatrics, School of Medicine.
Glista-Baker E; Center for Environmental Medicine, Asthma and Lung Biology, and.
Hoffman JR; Curriculum for the Environment and Ecology, College of Arts and Sciences.
Duffney PF; Curriculum in Toxicology and Environmental Medicine.
Robinette C; Center for Environmental Medicine, Asthma and Lung Biology, and.
Speen AM; Curriculum in Toxicology and Environmental Medicine.
Pawlak EA; Center for Environmental Medicine, Asthma and Lung Biology, and.
Dhingra R; Institute for Environmental Health Solutions, and.; Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Noah TL; Center for Environmental Medicine, Asthma and Lung Biology, and.; Department of Pediatrics, School of Medicine.
Jaspers I; Curriculum in Toxicology and Environmental Medicine.; Center for Environmental Medicine, Asthma and Lung Biology, and.; Department of Pediatrics, School of Medicine.; Institute for Environmental Health Solutions, and.
Źródło:
American journal of respiratory cell and molecular biology [Am J Respir Cell Mol Biol] 2021 Jan; Vol. 64 (1), pp. 126-137.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2000- : New York, NY : American Thoracic Society
Original Publication: [New York, NY : The Association, [c1989-
MeSH Terms:
Immunity, Mucosal/*drug effects
Influenza Vaccines/*immunology
Nasal Mucosa/*drug effects
Tobacco Products/*adverse effects
Vaccines, Attenuated/*immunology
Vaping/*adverse effects
Vaping/*immunology
Adult ; Cytokines/immunology ; Female ; Humans ; Immunity, Innate/drug effects ; Immunity, Innate/immunology ; Immunity, Mucosal/immunology ; Inflammation/immunology ; Inflammation/virology ; Influenza, Human/immunology ; Influenza, Human/virology ; Male ; Nasal Lavage Fluid/immunology ; Nasal Lavage Fluid/virology ; Nasal Mucosa/immunology ; Smoke/adverse effects ; Young Adult
References:
J Emerg Med. 2014 Jul;47(1):15-7. (PMID: 24462024)
Lancet. 2020 Apr 11;395(10231):1225-1228. (PMID: 32178769)
Environ Health Perspect. 2011 Jan;119(1):78-83. (PMID: 20920950)
Vaccine. 2002 Jan 31;20(9-10):1340-53. (PMID: 11818152)
Mil Med. 1982 Jan;147(1):43-8. (PMID: 6806680)
Am J Respir Crit Care Med. 2020 Dec 1;202(11):1540-1550. (PMID: 32692579)
Nat Rev Immunol. 2016 Oct;16(10):626-38. (PMID: 27546235)
PLoS One. 2014 Jun 09;9(6):e98671. (PMID: 24910991)
J Appl Toxicol. 2019 Aug;39(8):1143-1154. (PMID: 30957912)
N Engl J Med. 2020 Feb 20;382(8):689-691. (PMID: 31951683)
Am J Physiol Lung Cell Mol Physiol. 2019 Mar 1;316(3):L470-L486. (PMID: 30604630)
Curr Clin Microbiol Rep. 2019 Mar;6(1):10-17. (PMID: 31592409)
Thorax. 2018 Jun;73(6):546-556. (PMID: 29079611)
Chest. 2016 Mar;149(3):e65-7. (PMID: 26965975)
Front Immunol. 2018 Feb 13;9:245. (PMID: 29497422)
Chin Med J (Engl). 2004 Aug;117(8):1123-9. (PMID: 15361282)
Eval Health Prof. 2019 Mar;42(1):118-124. (PMID: 30477337)
Toxicol Sci. 2005 Jun;85(2):990-1002. (PMID: 15772371)
Influenza Other Respir Viruses. 2019 Sep;13(5):429-437. (PMID: 31225704)
Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L52-L66. (PMID: 28428175)
Respir Res. 2011 Aug 04;12:102. (PMID: 21816072)
Adv Exp Med Biol. 2016;910:39-45. (PMID: 26987337)
Drug Alcohol Depend. 2019 Jan 1;194:363-370. (PMID: 30472577)
J Immunol. 2019 Jan 15;202(2):351-359. (PMID: 30617116)
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52. (PMID: 25352553)
Tob Control. 2019 Mar;28(2):146-151. (PMID: 29853561)
PLoS One. 2014 Jul 02;9(7):e101364. (PMID: 24988208)
Cell Immunol. 2004 Jul;230(1):1-9. (PMID: 15541713)
Clin Respir J. 2018 Mar;12(3):1295-1299. (PMID: 29392888)
N Engl J Med. 1982 Oct 21;307(17):1042-6. (PMID: 7121513)
Expert Rev Vaccines. 2011 Aug;10(8):1131-41. (PMID: 21854309)
PLoS Pathog. 2016 Feb 18;12(2):e1005374. (PMID: 26891052)
Am J Physiol Lung Cell Mol Physiol. 2017 Feb 1;312(2):L288-L296. (PMID: 28011618)
Clin Immunol. 2012 Mar;142(3):232-6. (PMID: 22264637)
Arch Intern Med. 2004 Nov 8;164(20):2206-16. (PMID: 15534156)
Autoimmun Rev. 2018 Feb;17(2):142-154. (PMID: 29180124)
Am J Respir Cell Mol Biol. 2001 Jun;24(6):769-77. (PMID: 11415944)
J Asthma. 2020 Nov;57(11):1168-1172. (PMID: 31352844)
Am J Physiol Lung Cell Mol Physiol. 2015 Dec 1;309(11):L1313-22. (PMID: 26432867)
Eur J Immunol. 2013 Oct;43(10):2613-25. (PMID: 23857287)
J Vis Exp. 2013 Oct 08;(80):. (PMID: 24145828)
Am J Respir Crit Care Med. 2018 Feb 15;197(4):492-501. (PMID: 29053025)
Am J Physiol Lung Cell Mol Physiol. 2016 Mar 1;310(5):L415-25. (PMID: 26684252)
Am J Respir Crit Care Med. 2019 Apr 15;199(8):996-1007. (PMID: 30360637)
Tob Control. 2019 Nov;28(6):623-628. (PMID: 30733312)
Am J Physiol Lung Cell Mol Physiol. 2017 Aug 1;313(2):L193-L206. (PMID: 28522559)
Am J Public Health. 1981 May;71(5):530-2. (PMID: 7212144)
Pediatrics. 2018 Jun;141(6):. (PMID: 29773665)
Am J Respir Crit Care Med. 2019 Nov 1;200(9):1134-1145. (PMID: 31170808)
Am J Physiol Cell Physiol. 2020 Jan 1;318(1):C205-C214. (PMID: 31664858)
Am J Respir Crit Care Med. 2019 Dec 1;200(11):1392-1401. (PMID: 31390877)
Prev Med Rep. 2016 Jun 10;4:169-78. (PMID: 27413679)
Cell Tissue Res. 2018 Mar;371(3):399-406. (PMID: 29404726)
PLoS Pathog. 2011 Jul;7(7):e1002149. (PMID: 21829352)
Chem Res Toxicol. 2019 Jun 17;32(6):982-985. (PMID: 31117350)
Physiol Rev. 2019 Apr 1;99(2):1223-1248. (PMID: 30758246)
Nat Immunol. 2019 May;20(5):593-601. (PMID: 30886417)
Sci Rep. 2019 May 2;9(1):6844. (PMID: 31048778)
PLoS Pathog. 2008 Feb 29;4(2):e1000006. (PMID: 18389078)
Am J Physiol Lung Cell Mol Physiol. 2017 Aug 1;313(2):L278-L292. (PMID: 28495856)
Sci Rep. 2018 Feb 21;8(1):3394. (PMID: 29467466)
NPJ Vaccines. 2019 Jul 12;4:29. (PMID: 31312529)
Prev Med Rep. 2016 Nov 11;5:33-40. (PMID: 27896041)
Thorax. 2018 Dec;73(12):1161-1169. (PMID: 30104262)
Am J Physiol Lung Cell Mol Physiol. 2016 Jul 1;311(1):L135-44. (PMID: 27288488)
J Clin Invest. 2019 Oct 1;129(10):4290-4304. (PMID: 31483291)
Grant Information:
P30 ES010126 United States ES NIEHS NIH HHS; P50 HL120100 United States HL NHLBI NIH HHS; T32 ES007126 United States ES NIEHS NIH HHS
Contributed Indexing:
Keywords: e-cigarette; immune; influenza; respiratory; virus
Molecular Sequence:
ClinicalTrials.gov NCT02019745
Substance Nomenclature:
0 (Cytokines)
0 (Influenza Vaccines)
0 (Smoke)
0 (Vaccines, Attenuated)
Entry Date(s):
Date Created: 20201023 Date Completed: 20210201 Latest Revision: 20210824
Update Code:
20240105
PubMed Central ID:
PMC7781000
DOI:
10.1165/rcmb.2020-0164OC
PMID:
33095645
Czasopismo naukowe
Inhalation of tobacco smoke has been linked to increased risk of viral infection, such as influenza. Inhalation of electronic-cigarette (e-cigarette) aerosol has also recently been linked to immune suppression within the respiratory tract, specifically the nasal mucosa. We propose that changes in the nasal mucosal immune response modify antiviral host-defense responses in e-cigarette users. Nonsmokers, cigarette smokers, and e-cigarette users were inoculated with live-attenuated influenza virus (LAIV) to safely examine the innate immune response to influenza infection. Before and after LAIV inoculation, we collected nasal epithelial-lining fluid, nasal lavage fluid, nasal-scrape biopsy specimens, urine, and blood. Endpoints examined include cytokines and chemokines, influenza-specific IgA, immune-gene expression, and markers of viral load. Statistical analysis included primary comparisons of cigarette and e-cigarette groups with nonsmokers, as well as secondary analysis of demographic factors as potential modifiers. Markers of viral load did not differ among the three groups. Nasal-lavage-fluid anti-LAIV IgA levels increased in nonsmokers after LAIV inoculation but did not increase in e-cigarette users and cigarette smokers. LAIV-induced gene-expression changes in nasal biopsy specimens differed in cigarette smokers and e-cigarette users as compared with nonsmokers, with a greater number of genes changed in e-cigarette users, mostly resulting in decreased expression. The top downregulated genes in cigarette smokers were SMPD3 , NOS2A , and KLRB1 , and the top downregulated genes in e-cigarette users were MR1 , NT5E , and HRAS . Similarly, LAIV-induced cytokine levels in nasal epithelial-lining fluid differed among the three groups, including decreased antiviral host-defense mediators (IFNγ, IL6, and IL12p40). We also detected that sex interacted with tobacco-product exposure to modify LAIV-induced immune-gene expression. Our results demonstrate that e-cigarette use altered nasal LAIV-induced immune responses, including gene expression, cytokine and chemokine release, and LAIV-specific IgA levels. Together, these data suggest that e-cigarette use induces changes in the nasal mucosa that are consistent with the potential for altered respiratory antiviral host-defense function.Clinical trial registered with www.clinicaltrials.gov (NCT02019745).
Comment in: Am J Respir Cell Mol Biol. 2021 Jan;64(1):16-18. (PMID: 33217237)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies